CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Sacubitrilo/valsartán

Biblioteca de referencias

Detalles
G
ESPACIO de sacubitrilo/valsartán › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por el módulo que las cita y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los 101 artículos y guías citados, por año, y lo que se espera de los estudios en marcha

5101511111751451211109149PARADIGM-HFPIONEER-HF y PARAGON-HFPARADISE-MIPANORAMA-HFhoyNAUTICALdic. 2026NCT06917664dic. 2026SAVA-TTRabr. 2027MAINSTREAMdic. 2027CRACOVIA-HFago. 202820102012201420162018202020222024202620282030Lo que viene: NAUTICAL (dic. 2026) · NCT06917664 (dic. 2026) · SAVA-TTR (abr. 2027) · MAINSTREAM (dic. 2027) · CRACOVIA-HF (ago. 2028)
101artículos y guías: 100 en PubMed y 1 fuera, en Vancouver2fichas técnicas: sacubitrilo/valsartán y enalapril10estudios en ClinicalTrials.gov: 5 en marcha y 5 cerrados

Cada referencia, comprobada en PubMed, CIMA o ClinicalTrials.gov el 19/10/2026, y descargable en RIS (113 referencias). A la derecha de la raya de hoy, los resultados primarios previstos en el registro de cada estudio en marcha.

Descargar en RIS (113 referencias)

Artículos y guías en PubMed (100)

  1. Anguita-Gámez M, Bonilla-Palomas JL, Recio-Mayoral A, González-Manzanares R, Muñiz-García J, Romero-Rodríguez N, et al. Differences in clinical features and 1-year outcomes of patients with heart failure and reduced, mildly reduced, and preserved ejection fraction in a contemporary cohort: is the clinical profile changing? Clin Res Cardiol. 2026;115(9):1486-1497. doi:10.1007/s00392-025-02632-5 · PMID 40111443G3
  2. Bhatt AS, Vaduganathan M, Solomon SD, Schneeweiss S, Lauffenburger JC, Desai RJ. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries. Eur J Heart Fail. 2022;24(9):1506-1515. doi:10.1002/ejhf.2572 · PMID 35689603G3
  3. Bitar YSL, Durães AR, de Macedo CRB, Aras MG, Santos LC, de Abreu RSF, et al. Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. J Hypertens. 2025;43(9):1485-1491. doi:10.1097/HJH.0000000000004075 · PMID 40621831G5
  4. Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN, et al. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation. 2025;152(25):1742-1755. doi:10.1161/CIRCULATIONAHA.125.073322 · PMID 41230611G2G5I1
  5. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654G1
  6. Cabral J, Vasconcelos H, Maia-Araújo P, Moreira E, Campelo M, Amorim S, et al. Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic. Cardiovasc Diagn Ther. 2021;11(6):1217-1227. doi:10.21037/cdt-21-312 · PMID 35070791G3
  7. Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129-137. doi:10.1002/ejhf.687 · PMID 27868321I2
  8. Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, Greene SJ, Mentz RJ, et al. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2021;9(12):876-886. doi:10.1016/j.jchf.2021.06.018 · PMID 34509408G3
  9. Carnicelli AP, Lippmann SJ, Greene SJ, Mentz RJ, Greiner MA, Hardy NC, et al. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. J Card Fail. 2021;27(8):826-836. doi:10.1016/j.cardfail.2021.03.012 · PMID 34364659G3
  10. Cho DH, Choi J, Youn JC, Kim MN, Lee CJ, Son JW, et al. Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction. ESC Heart Fail. 2025;12(1):603-612. doi:10.1002/ehf2.15117 · PMID 39420468G3
  11. Cikes M, Brugts JJ, Claggett B, Jorde UP, Milicic D, Planinc I, et al. Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy: Primary Results of the ENVAD-HF Trial. JACC Heart Fail. 2025;13(11):102657. doi:10.1016/j.jchf.2025.102657 · PMID 40892548G2
  12. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018;6(6):489-498. doi:10.1016/j.jchf.2018.02.004 · PMID 29655829C6
  13. Dattilo G, Licordari R, Imbalzano E, Cannata A, Agostoni P, Aimo A, et al. Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study. ESC Heart Fail. 2026;13(2). doi:10.1093/eschf/xvag082 · PMID 41843757G3
  14. de Frutos F, Mirabet S, Ortega-Paz L, Buera I, Darnés S, Farré N, et al. Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry. ESC Heart Fail. 2020;7(1):25-35. doi:10.1002/ehf2.12567 · PMID 31916413G3
  15. de la Espriella R, Bayés-Genís A, Morillas H, Bravo R, Vidal V, Núñez E, et al. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. ESC Heart Fail. 2020;7(6):3792-3800. doi:10.1002/ehf2.12965 · PMID 32964683G3
  16. Delgado-Jiménez JF, Segovia-Cubero J, Almenar-Bonet L, de Juan-Bagudá J, Lara-Padrón A, García-Pinilla JM, et al. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics. J Clin Med. 2022;11(5). doi:10.3390/jcm11051170 · PMID 35268260G3
  17. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2(1):79-85. doi:10.1001/jamacardio.2016.4733 · PMID 27842179C6
  18. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019;322(11):1077-1084. doi:10.1001/jama.2019.12843 · PMID 31475296G2
  19. Desai RJ, Patorno E, Vaduganathan M, Mahesri M, Chin K, Levin R, et al. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021;107(17):1407-1416. doi:10.1136/heartjnl-2021-319405 · PMID 34088766G3
  20. Dhont S, Moura Ferreira S, Galloo X, Martens P, Meekers E, Tartaglia K, et al. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation. 2026;153(25):1973-1983. doi:10.1161/CIRCULATIONAHA.126.080833 · PMID 42104906G2G5I1
  21. Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, et al. Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). J Clin Med. 2023;12(2). doi:10.3390/jcm12020699 · PMID 36675628G3
  22. Díez-Villanueva P, Vicent L, de la Cuerda F, Esteban-Fernández A, Gómez-Bueno M, de Juan-Bagudá J, et al. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan. Cardiology. 2020;145(5):275-282. doi:10.1159/000505148 · PMID 31940620G3
  23. Escobar C, Palacios B, Varela L, Gutiérrez M, Duong M, Chen H, et al. Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. J Clin Med. 2022;11(17). doi:10.3390/jcm11175199 · PMID 36079133G3
  24. Esteban-Fernández A, Díez-Villanueva P, Vicent L, Bover R, Gómez-Bueno M, De Juan J, et al. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol. 2020;55(2):65-69. doi:10.1016/j.regg.2019.10.002 · PMID 31892433G3
  25. Eworuke E, Welch EC, Haug N, Horgan C, Lee HS, Zhao Y, et al. Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors. J Am Coll Cardiol. 2023;81(4):321-331. doi:10.1016/j.jacc.2022.10.033 · PMID 36697132G3
  26. Fu M, Vedin O, Svennblad B, Lampa E, Johansson D, Dahlström U, et al. Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Fail. 2020;7(6):3633-3643. doi:10.1002/ehf2.12883 · PMID 32881399G3
  27. Fu M, Pivodic A, Käck O, Costa-Scharplatz M, Dahlström U, Lund LH. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction. Clin Res Cardiol. 2023;112(1):167-174. doi:10.1007/s00392-022-02124-w · PMID 36443599G3
  28. Fujimoto W, Matsumoto S, Kanaoka K, Nasu T, Kida K, Kagiyama N, et al. Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry. J Cardiol. 2025;86(2):202-208. doi:10.1016/j.jjcc.2025.02.012 · PMID 39954722G3
  29. Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(5):3547-3556. doi:10.1002/ehf2.13547 · PMID 34338429G3
  30. Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, et al. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021;10(16):e021459. doi:10.1161/JAHA.121.021459 · PMID 34350772G3
  31. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61-73. doi:10.1016/S0140-6736(18)32484-X · PMID 30429050C6
  32. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C6
  33. Hanon O, Cohen A, Jourdain P, Leray E, de Pouvourville G, Goguillot M, et al. Real-world persistence with sacubitril/valsartan in patients with heart failure in France: A claims database study. Arch Cardiovasc Dis. 2026;119(6-7):430-440. doi:10.1016/j.acvd.2025.11.010 · PMID 41506924G3
  34. Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018;138(15):1505-1514. doi:10.1161/CIRCULATIONAHA.118.034818 · PMID 30002098G2G5
  35. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 · PMID 35363499G1
  36. Hsu YL, Lee CH, Chung WP, Lee WH, Lee KT, Tsai JH, et al. Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy. Eur J Heart Fail. 2025;27(11):2141-2151. doi:10.1002/ejhf.3758 · PMID 40637120G5
  37. Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67-76. doi:10.1111/jch.13437 · PMID 30536595G5
  38. Iacoviello M, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, et al. Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF. ESC Heart Fail. 2024;11(1):456-465. doi:10.1002/ehf2.14600 · PMID 38041517G3
  39. Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085-1095. doi:10.1001/jama.2019.12821 · PMID 31475295C4G2
  40. Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576-84. doi:10.1093/eurheartj/ehv330 · PMID 26231885C6
  41. Jung K, Kim JH, Bea S, Ko HY, You SC, Choi EK, et al. Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(5):412-421. doi:10.1093/ehjcvp/pvaf024 · PMID 40397431G3
  42. Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation. 2019;139(11):1354-1365. doi:10.1161/CIRCULATIONAHA.118.037077 · PMID 30586756G2G5
  43. Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, et al. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. Eur J Heart Fail. 2019;21(11):1383-1397. doi:10.1002/ejhf.1532 · PMID 31132222G3
  44. Kittleson MM, Panjrath GS, Bates K, Breathett KK, Dixon DL, Januzzi JL Jr, et al. Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2026;88(15):1817-1846. doi:10.1016/j.jacc.2026.06.018 · PMID 42494134G1
  45. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420G1
  46. Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, et al. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA Cardiol. 2023;8(4):366-375. doi:10.1001/jamacardio.2023.0065 · PMID 36884247G2G5
  47. Lee V, Dalakoti M, Zheng Q, Toh DF, Boubertakh R, Bryant JA, et al. Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. Nat Commun. 2025;16(1):6981. doi:10.1038/s41467-025-62203-0 · PMID 40739095G5
  48. Lim J, Lee HJ, Kwak S, Kim B, Han KD, Lee H, et al. Clinical outcomes according to the average daily dose of sacubitril/valsartan: a nationwide longitudinal cohort study. Clin Res Cardiol. 2026;115(9):1455-1466. doi:10.1007/s00392-025-02602-x · PMID 40100325G3
  49. Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, et al. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. JAMA. 2026;335(1):49-59. doi:10.1001/jama.2025.19808 · PMID 41335448G2I1
  50. Lopez-Aguilera J, Perea-Armijo J, Muñoz-Villarreal AB, Cepas-Sosa A, Luque-Serrano LM, Aguayo-Caño N, et al. Nurse Specialising Consultation in Heart Failure: Impact on Drug Titration and Cardiovascular Events in Patients with Heart Failure and Reduced Ejection Fraction. J Clin Med. 2025;14(18). doi:10.3390/jcm14186681 · PMID 41010885D4
  51. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, et al. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). JACC Heart Fail. 2017;5(4):305-309. doi:10.1016/j.jchf.2016.12.018 · PMID 28359417G3
  52. López-Azor JC, Vicent L, Valero-Masa MJ, Esteban-Fernández A, Gómez-Bueno M, Pérez Á, et al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail. 2019;6(6):1161-1166. doi:10.1002/ehf2.12527 · PMID 31701680G3
  53. Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-1488. doi:10.1016/j.jacc.2023.12.024 · PMID 38466244G1
  54. Madrini V Jr, Souza PVR, Fernandes F, Ianni BM, Martins AS, Luzuriaga GJ, et al. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. J Am Coll Cardiol. 2026;87(10):1220-1232. doi:10.1016/j.jacc.2025.10.053 · PMID 41396086G2I1
  55. Maggioni AP, Clark AL, Barrios V, Damy T, Drozdz J, Fonseca C, et al. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry. ESC Heart Fail. 2022;9(6):4209-4218. doi:10.1002/ehf2.14014 · PMID 36106548G3
  56. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480 · PMID 37345492G1
  57. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17-25. doi:10.1001/jamacardio.2021.4567 · PMID 34730769C6G2
  58. Matsumoto S, McMurray JJV, Nasu T, Ishii S, Kagiyama N, Kida K, et al. Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. J Cardiol. 2024;84(2):133-140. doi:10.1016/j.jjcc.2023.11.005 · PMID 38000538G3
  59. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368 · PMID 34447992G1
  60. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195 · PMID 37622666G1
  61. McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37(4):531-546. doi:10.1016/j.cjca.2021.01.017 · PMID 33827756G1
  62. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178 · PMID 39210715G1
  63. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077 · PMID 25176015C4C7G2I1
  64. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. doi:10.1016/j.jacc.2023.04.019 · PMID 37212758G2H3I1
  65. Molina A, Vicente M, Gasol M, Carbonell P, López P, Pontes C. A Drug Utilization Study of Sacubitril/Valsartan in Catalonia. Rev Esp Cardiol (Engl Ed). 2019;72(7):593-595. doi:10.1016/j.rec.2018.08.004 · PMID 30172655C2
  66. Mucherino S, Dima AL, Coscioni E, Vassallo MG, Orlando V, Menditto E. Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure. Pharmaceutics. 2023;15(11). doi:10.3390/pharmaceutics15112568 · PMID 38004547G3
  67. Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019;73(11):1264-1272. doi:10.1016/j.jacc.2019.01.018 · PMID 30846338I1
  68. Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW, et al. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152(16):1136-1145. doi:10.1161/CIRCULATIONAHA.125.076616 · PMID 40884047C6G2G5I1
  69. Oyanguren J, García-Garrido L, Nebot Margalef M, Lekuona I, Comin-Colet J, Manito N, et al. Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol. ESC Heart Fail. 2017;4(4):507-519. doi:10.1002/ehf2.12152 · PMID 29154427D4
  70. Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, Latorre-García P, Torcal-Laguna J, Comín-Colet J, et al. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. Rev Esp Cardiol (Engl Ed). 2021;74(6):533-543. doi:10.1016/j.rec.2020.04.016 · PMID 32591295D4
  71. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021;385(20):1845-1855. doi:10.1056/NEJMoa2104508 · PMID 34758252G2G5I1
  72. Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021;326(19):1919-1929. doi:10.1001/jama.2021.18463 · PMID 34783839G2
  73. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45(5):824-833. doi:10.1038/s41440-021-00819-7 · PMID 35058583G5
  74. Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/j.jacc.2024.11.009 · PMID 40013746G1
  75. Roca LN, García MC, Germán JB, Becerra AJB, Otero JMR, Chapel JAE, et al. Use and Benefit of Sacubitril/Valsartan in Elderly Patients with Heart Failure with Reduced Ejection Fraction. J Clin Med. 2024;13(16). doi:10.3390/jcm13164772 · PMID 39200914G3
  76. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255-66. doi:10.1016/S0140-6736(09)61966-8 · PMID 20236700G5
  77. Ruiz-Bustillo S, Vicente M, Ruiz-Rodriguez P, Linás-Alonso AM, Valdivielso-Moré S, Farré N, et al. Effectiveness of a nurse-led telemedicine-based program for pharmacological and prognostic optimization of patients with heart failure and reduced ejection fraction: the MAR-HF-Titration study. Eur J Cardiovasc Nurs. 2025;24(8):1365-1374. doi:10.1093/eurjcn/zvaf161 · PMID 40795350D4
  78. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-340. doi:10.1016/S2213-8587(17)30087-6 · PMID 28330649C6
  79. Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193-202. doi:10.1002/ejhf.548 · PMID 27170530C4G2
  80. Senni M, McMurray JJV, Wachter R, McIntyre HF, Anand IS, Duino V, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail. 2018;20(3):491-500. doi:10.1002/ejhf.1054 · PMID 29164797C4
  81. Shaddy R, Burch M, Kantor PF, Solar-Yohay S, Garito T, Zhang S, et al. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation. 2024;150(22):1756-1766. doi:10.1161/CIRCULATIONAHA.123.066605 · PMID 39319469C6G2
  82. Soler-Rangel L, Méndez-Bailón M, Pérez-Silvestre J, Fernández-Rodríguez JM, García BC, Argüelles-Curto A, et al. Effectiveness of sacubitril-varsartan versus angiotensin converting enzyme inhibitors in patients hospitalized for acute heart failure: a retrospective cohort study of the RICA registry. J Geriatr Cardiol. 2022;19(11):802-810. doi:10.11909/j.issn.1671-5411.2022.11.010 · PMID 36561058G3
  83. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95. doi:10.1016/S0140-6736(12)61227-6 · PMID 22932717G2
  84. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655 · PMID 31475794G2G5
  85. Stolfo D, Benson L, Lindberg F, Dahlström U, Käck O, Sinagra G, et al. Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024;26(10):2243-2257. doi:10.1002/ejhf.3404 · PMID 39078343G3
  86. Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I, et al. In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial. Eur Heart J. 2024;45(42):4482-4493. doi:10.1093/eurheartj/ehae561 · PMID 39215531G2H3
  87. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Circ J. 2021;85(5):584-594. doi:10.1253/circj.CJ-20-0854 · PMID 33731544G2
  88. Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023;44(31):2982-2993. doi:10.1093/eurheartj/ehad344 · PMID 37210743G2G5H3
  89. Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, et al. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018;198:145-151. doi:10.1016/j.ahj.2018.01.004 · PMID 29653636H3
  90. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851 · PMID 30415601C4C6G2H3
  91. Velicki L, Popovic D, Okwose NC, Preveden A, Tesic M, Tafelmeier M, et al. Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM). Eur J Heart Fail. 2024;26(6):1361-1368. doi:10.1002/ejhf.3291 · PMID 38800948G2G5I1
  92. Vicent L, Esteban-Fernández A, Gómez-Bueno M, De-Juan J, Díez-Villanueva P, Iniesta ÁM, et al. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial. J Cardiovasc Pharmacol. 2018;72(2):112-116. doi:10.1097/FJC.0000000000000603 · PMID 29878937G3
  93. Vicent L, Esteban-Fernández A, Gómez-Bueno M, De-Juan J, Díez-Villanueva P, Iniesta ÁM, et al. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry. J Cardiovasc Pharmacol. 2019;73(2):118-124. doi:10.1097/FJC.0000000000000641 · PMID 30540687G3
  94. Virani S, Zieroth S, Aleksova N, Anderson K, Clarke B, Ducharme A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%). Can J Cardiol. 2025;41(10):1857-1874. doi:10.1016/j.cjca.2025.07.027 · PMID 41110921G1
  95. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588-597. doi:10.1002/ejhf.1465 · PMID 30972918G3
  96. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998-1007. doi:10.1002/ejhf.1498 · PMID 31134724C4G2H3
  97. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411-420. doi:10.1161/HYPERTENSIONAHA.116.08556 · PMID 28093466G2G5
  98. Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, et al. Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study). J Clin Hypertens (Greenwich). 2025;27(1):e14938. doi:10.1111/jch.14938 · PMID 39632589G5
  99. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803. doi:10.1016/j.jacc.2017.04.025 · PMID 28461007G1
  100. Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, et al. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):469-477. doi:10.1093/ehjqcco/qcab019 · PMID 33725113G3

Otros documentos con DOI (1)

  1. Morgado García-Polavieja JI, Sigismondi A, Ortiz Cruces S, Gálvez Ríos E, López Aguilar JR, Manovel Sánchez AJ, et al. Impact of sacubitril/valsartan on the indication for defibrillator and left ventricular remodeling: real life data. REC: CardioClinics. 2022;57(3):172-181. doi:10.1016/j.rccl.2021.12.005G3

Fichas técnicas (CIMA, AEMPS) (2)

  1. Ficha técnica de enalapril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 63355C5
  2. Ficha técnica de sacubitrilo/valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 1151058003B2B5C1C4C5C6C7G5H3I1I2

Estudios en ClinicalTrials.gov (10)

  1. CRACOVIA-HF. Sacubitrilo/valsartán frente a ramipril en insuficiencia cardiaca isquémica con FEVI en rango medio (40-49%): cambio del volumen telesistólico del ventrículo izquierdo a los 12 meses. ClinicalTrials.gov, NCT05508035; 488 pacientes · fase III, reclutando · resultados primarios previstos: agosto de 2028 · promotor: John Paul II Hospital (Cracovia). Consultado el 19/10/2026. NCT05508035I1
  2. MAINSTREAM. Sacubitrilo/valsartán frente a placebo en la prevención primaria de la cardiotoxicidad del tratamiento del cáncer de mama con antraciclinas o anti-HER2, con FEVI basal ≥50%: cambio de la FEVI de un 5% o más en 24 meses. ClinicalTrials.gov, NCT05465031; 600 pacientes · fase IV, reclutando · resultados primarios previstos: diciembre de 2027 · promotor: Silesian Centre for Heart Diseases. Consultado el 19/10/2026. NCT05465031I1
  3. NAUTICAL. Aumento de los péptidos natriuréticos con sacubitrilo/valsartán frente a valsartán en adultos de raza negra autoidentificada sin enfermedad cardiovascular ni diabetes: sensibilidad a la insulina y gasto energético a las 12 semanas. ClinicalTrials.gov, NCT04055428; 200 pacientes · fase II, reclutando · resultados primarios previstos: diciembre de 2026 · promotor: University of Alabama at Birmingham. Consultado el 19/10/2026. NCT04055428I1
  4. NCT06917664. Sacubitrilo/valsartán tras cirugía coronaria aislada en la insuficiencia mitral isquémica moderada, frente a no darlo: área efectiva del orificio regurgitante a los 6 meses. ClinicalTrials.gov, NCT06917664; 220 pacientes · fase IV, reclutando · resultados primarios previstos: diciembre de 2026 · promotor: China National Center for Cardiovascular Diseases. Consultado el 19/10/2026. NCT06917664I1
  5. PARACHUTE-HF. Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC. ClinicalTrials.gov, NCT04023227; completado, con resultados publicados en el registro · última actualización del registro, 11/05/2026. Consultado el 19/10/2026. NCT04023227G2
  6. PARADIGM-HF. This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure. ClinicalTrials.gov, NCT01035255; detenido antes de tiempo, con resultados publicados en el registro · última actualización del registro, 15/08/2016. Consultado el 19/10/2026. NCT01035255C4
  7. PERSPECTIVE. Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction. ClinicalTrials.gov, NCT02884206; completado, con resultados publicados en el registro · última actualización del registro, 06/08/2024. Consultado el 19/10/2026. NCT02884206G2I2
  8. PROVE-HF. Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. ClinicalTrials.gov, NCT02887183; completado, con resultados publicados en el registro · última actualización del registro, 07/10/2021. Consultado el 19/10/2026. NCT02887183C4
  9. SAVA-TTR. Sacubitrilo/valsartán frente a no iniciarlo, abierto, en la amiloidosis cardiaca por transtiretina con FEVI ≤40%: cambio de la FEVI a los 12 meses. ClinicalTrials.gov, NCT06712030; 114 pacientes · fase III; según el registro, aún sin reclutar (última actualización, 02/12/2024) · resultados primarios previstos: abril de 2027 · promotor: Hospital Universitario Puerta de Hierro. Consultado el 19/10/2026. NCT06712030I1
  10. TRANSITION. Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event. ClinicalTrials.gov, NCT02661217; completado, con resultados publicados en el registro · última actualización del registro, 26/04/2021. Consultado el 19/10/2026. NCT02661217C4
La lista se genera sola a partir de lo que citan los módulos (PubMed por PMID, DOI resuelto en PubMed o en CrossRef, CIMA y ClinicalTrials.gov) y se rehace al regenerar el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.